Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer

Key facts

Sponsor

M.D. Anderson Cancer Center

Principal Investigator

Sunyoung Lee

M.D. Anderson Cancer Center

Intervention

Fluorouracil(drug)

Enrollment

15 target

Eligibility

12 years · All sexes

Timeline

2021 – 2028

Study locations (1)

• M D Anderson Cancer Center, Houston, Texas, United States

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Fibrolamellar hepatocellular carcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT06789198
  Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma Patients and Other Tumor Entities Carrying the Driver Fusion DNAJB1-PRKACA
  University Hospital Tuebingen
• RECRUITINGPHASE1, PHASE2NCT06620302
  Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma
  Children's Oncology Group
• RECRUITINGPHASE1, PHASE2NCT06027086
  DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• RECRUITINGPHASE1NCT05937295
  FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined with Immune Checkpoint Inhibition
  University Hospital Tuebingen
• RECRUITINGPHASE1, PHASE2NCT05468359
  Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
  St. Jude Children's Research Hospital
• RECRUITINGPHASE2NCT04134559
  Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
  Allison O'Neill, MD

See all trials for Fibrolamellar hepatocellular carcinoma →